【摘 要】
:
Aims: Antiplatelet treatment could cause a change in plasma levels of platelet microRNAs (miRNAs).However, it is not clear whether the plasma level of platelet miRNAs can predict clinical outcomes of
【机 构】
:
Medical Research Center of Guangdong General Hospital Guangzhou 510080,China;Department of Cardiolog
【出 处】
:
中国药理学会药物临床试验专业委员会首届学术研讨会
论文部分内容阅读
Aims: Antiplatelet treatment could cause a change in plasma levels of platelet microRNAs (miRNAs).However, it is not clear whether the plasma level of platelet miRNAs can predict clinical outcomes of antiplatelet treatment.The present study aimed to evaluate the association of plasma miR-16, miR-21, miR-126, miR-26b, and miR-223 with the risk of clinical outcomes in dual antiplatelet-treated patients after percutaneous coronary intervention (PCI).Methods and results: A total of 491 Han Chinese patients who had received PCI and dual antiplatelet therapy were sequentially recruited to the study and followed for up to one year.Plasma concentrations of five candidate miRNAs early the next morning after PCI were determined by quantitative reverse transcription PCR.The effect of the plasma miRNA level on major adverse cardiovascular events (MACE) within one year and bleeding within six months were assessed.We found that a higher plasma miR-126 level was significantly associated with a higher risk in terms of time-to-MACE.When compared with the plasma miR-126 level in the first three quartiles, the hazard ratio (HR) for the plasma miR-126 level in the fourth quartile was 2.61 (95% CI: 1.32-5.18, p=0.006).Multivariable Cox regression analysis showed that diabetes mellitus, ejection fraction, hypertension and a higher plasma miR-126 level were independent risk factors for MACE.Plasma miR-223 level was not an independent predictive marker for MACE.There was no significant association between the level of 5 plasma miRNAs and bleeding events during six-month follow-up.Conclusions: Based on these results, we suggest that plasma miR-126 could be a potential marker for predicting major adverse cardiac events in patients after PCI.
其他文献
目的:建立检测人血浆中奥美拉唑及其代谢物5-羟基奥美拉唑和奥美拉唑砜的高效液相色谱法.方法:血浆中奥美拉唑和其代谢物及内标非那西丁经乙酸乙酯和正己烷提取,采用Zorbax SB-C18(4.6×150 mm,5μm)色谱柱分离.流动相:乙腈-水-0.1%三氟乙酸,流速1.0mL.min-1;紫外检测波长:302nm(0-5.2min)、262nm(5.2-7.0min)、302nm(7.0-13.
目的:评价丙泊酚中/长链脂肪乳注射液在中国男性健康志愿者中的药动学和药效学.方法:20名中国男性健康志愿者按照随机、双盲、二阶段两药的自身交叉阳性对照试验设计,单次静脉注射试验药物或参比药物2mg/kg,采用高效液相色谱-质谱-质谱联用(HPLC-MS/MS)测定血药浓度,心电监护仪测定脑电双频谱指数(BIS),并观察试验期间不良事件.结果:20名志愿者均完成试验.丙泊酚体内处置过程符合权重系数为
目的:评价甘草与京大戟配伍对大鼠肠粘膜P-gp的影响.方法:对大鼠口服甘草煎液,京大戟煎液,甘草京大戟合煎液,生理盐水一周后,使用Ussing Chamber技术,评价罗丹明123(R123)和荧光素钠(CF)经大鼠小肠粘膜的经时吸收方向和分泌方向的透过量和表观渗透系数;应用RT-PCR技术评价mdr1a基因的表达情况;应用在体In situ实验研究甘草与京大戟合用对R123肠道给药后血浆中药物浓
目的:建立一个快速、高选择性的高效液相色谱串联质谱(LC-MS/MS)方法,用于人体药动学研究中测定人血浆中依菲巴特的含量.方法:以EPM-05为内标,采用固相萃取法提取血浆中依菲巴特与内标.采用Ultimate XB-C18(4.6mm×150mm,5μm),流动相乙腈-水(10mmol/L乙酸铵缓冲盐,0.1%甲酸)(32:68,v/v),流速为0.5 mL/min.采用ESI正离子模式,MR
新药Ⅰ期临床试验的研究对象以健康受试者为主(肿瘤药物外),受试者对试验的依从性是Ⅰ期临床试验成功的关键.本文旨在探讨在试验过程中如何合理管理受试者,增强受试者依从性,解决I期临床试验中一直面临的瓶颈问题,提高试验质量.通过举办讲座、参观学习、发布广告等方式提高招募受试者人数;知情同意过程做到充分知情、与受试者保持良好的沟通与足够的联系;受试者体检过程严格把关,遵从方案中入选和排除标准筛查;试验过程
目的:非诺多泮(Fenoldopam)是一快速作用的血管扩张剂,是DA1受体激动剂,主要刺激DA1受体诱导小动脉扩张.既可降低动脉压,又可扩张肾血管致肾血流增加.本文旨在建立高效快速分析人血浆中非诺多泮浓度的超高效液相-质谱联用(UPLC-MS/MS)分析方法.方法:采用奥沙西泮作为内标,2.5%氨水碱化血浆后以乙酸乙酯液液萃取的方法进行血浆样品预处理,吹干复溶后经Waters HSS T3 1.
目的:依非巴特(Eptifibatide)是人工合成的环状七肽,能够阻滞血小板聚集,用于治疗不稳定型心绞痛等心脑血管疾病.本文旨在评价依非巴特在中国健康人体内的药动学特征.方法:30名健康志愿者(男女各半)平均分为三个剂量组(45ug/kg、90ug/kg和180ug/kg),静脉推注.在给药后采集血液和尿液样本采用高效液相-质谱联用方法测定依非巴特的药物浓度.血药和尿药数据采用NONMEM 7.
目的:以茶碱作为CYP1A2在体探针药物,研究欧前胡素大鼠单次及多次给药后对茶碱药代动力学及其CYP1A2介导的8-羟化代谢产物1,3-二甲基尿酸药代动力学的影响,以探明欧前胡素对大鼠体内茶碱代谢的影响及其和CYP1A2酶活性和8-羟化代谢通路之间的关系.方法:采用HPLC方法检测大鼠血浆中茶碱(TP)和1,3-二甲基尿酸(1,3-DMU)的浓度.研究欧前胡素单次及多次给药后对大鼠体内茶碱及1,3
目的:观察含呋喃唑酮三联、四联疗法对Hp相关性十二指肠球部溃疡和慢性胃炎患者Hp的根除率.方法:来自全国16家医院的754例Hp感染者随机分为以下四组,1组和2组为四联10天/7天,方案:耐信20mg+丽珠得乐220mg+可莫西林1000mg+呋喃唑酮500mg,每日2次,7天/10天;3组和4组为三联7天/10天。方案:耐信20mg+阿莫西林1000mg+呋喃唑酮500mg,每日2次,10天/7